Dry Eye Research2024-10-23T10:27:49-05:00

Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye

Study Overview

A 4 weeks, Phase II, multicenter, randomized, double-masked, vehicle-controlled, parallel group study.

The study includes 12 weeks of follow-up to evaluate the safety and efficacy of recombinant human Nerve Growth Factor (rhNGF) eye drops solution versus vehicle in patients with moderate to severe dry eye (DE).

Further Reading:

The official study documentation is available here.

Contact Information:

For more information on the study or to enroll, please call Dr Goosey’s office at  713-558-8777.